Evaluation of in vivo bioactivity of a mutated streptokinase
Novelty in Biomedicine. 2017; 5 (2): 71-77
em Inglês
| IMEMR
| ID: emr-191068
ABSTRACT
Background:
Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don't affect the bioactivity of streptokinase is worthy. Recently, we modified the streptokinase through the elimination of 42 amino acids from its' C-terminal and assessed its bioactivity in vitro. In this study, bioactivity of the mutated-streptokinase determined and compared with those of commercially available streptokinase [Heberkinase] in rabbits with induced blood clot
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Novelty Biomed.
Ano de publicação:
2017
Similares
MEDLINE
...
LILACS
LIS